Ednrb

Ednrb Full Name

endothelin receptor type B

Ednrb Introduction

Endothelin Receptor Type B, also known as Ednrb, has become an increasingly important research target for scientists and drug developers trying to understand why vascular disorders, aggressive cancers, and neurodevelopmental diseases remain difficult to treat. As a G protein-coupled receptor activated primarily by endothelin peptides such as ET-1, EDNRB plays a central role in regulating vascular tone, neural crest cell migration, melanocyte development, inflammatory signaling, and tissue remodeling. Researchers have paid growing attention to this receptor because abnormal endothelin signaling is often linked to persistent disease progression, treatment resistance, and poor clinical outcomes. Structural biology studies published in recent years have further clarified how EDNRB interacts with multiple G proteins including Gs, Gi, and Gq, revealing the molecular basis of its highly diverse signaling behavior. These discoveries are particularly valuable for drug discovery teams seeking more selective endothelin receptor antagonists with improved efficacy and reduced off-target toxicity.

One reason EDNRB attracts significant clinical interest is its complex and sometimes contradictory role in human disease. In pulmonary arterial hypertension (PAH), excessive endothelin signaling contributes to pulmonary vasoconstriction, vascular remodeling, inflammation, and progressive right heart failure. Because patients with PAH often face delayed diagnosis and limited long-term treatment success, endothelin receptor antagonists have become a cornerstone of targeted therapy strategies. EDNRB is especially important because it participates not only in vasoconstrictive signaling but also in endothelin clearance and endothelial homeostasis, making selective modulation of the receptor biologically challenging yet therapeutically promising. Beyond cardiovascular disease, EDNRB dysfunction has also been associated with Hirschsprung disease, Waardenburg syndrome, enteric nervous system abnormalities, and pigment disorders due to its critical role during embryonic neural crest development. These connections make EDNRB highly relevant for translational research focused on developmental biology, regenerative medicine, and rare genetic diseases.

Cancer biology has further expanded the importance of Endothelin Receptor Type B as a therapeutic target. Elevated EDNRB expression has been reported in melanoma, glioma, and several other aggressive tumors where endothelin signaling can influence tumor cell migration, survival, angiogenesis, immune evasion, and phenotypic plasticity. Recent glioma studies demonstrated that EDNRB-dependent signaling suppresses proliferation while simultaneously promoting proneural-to-mesenchymal transition, a process strongly associated with tumor invasiveness and therapy resistance. In melanoma research, high-affinity nanobody-based targeting strategies directed against EDNRB are being explored as next-generation precision therapies aimed at improving tumor specificity and drug delivery efficiency. As researchers continue to uncover how EDNRB regulates calcium signaling, ERK/STAT3 activation, and tumor microenvironment interactions, the receptor is increasingly viewed not only as a biomarker of disease progression but also as a promising gateway for innovative targeted therapeutics across oncology, vascular medicine, and neurobiology.

Alternate Names for Ednrb

EDNRB; endothelin receptor type B; Etb; Ednra; endothelin B receptor; ET-B; ET-BR; endothelin-B receptor; endothelin receptor non-selective type;

• 1.Enevoldsen FC, et al.; Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy. J Clin Med. 2020, 9(3):824.
  2.Habib NG, et al.; Selection of Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension: A Comprehensive Narrative Review. Adv Ther. 2026, 43(2):468-519.